Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
ForeScout reports Q2 EPS 0c, consensus (31c) » 17:02
08/05/20
08/05
17:02
08/05/20
17:02
FSCT

ForeScout

$28.98 /

+0.01 (+0.03%)

Reports Q2 revenue…

Reports Q2 revenue $79.9M, consensus $77.38M. "I'm proud of our strong execution during the second quarter, despite many uncertainties. We closed strategic deals with both new and existing customers, made continued progress in the market with our eyeSegment product, and improved profitability," said Michael DeCesare, CEO and President of Forescout Technologies. "We look forward to completing our pending transaction with Advent International, and building upon our strategic cloud transformation and transition to a recurring subscription business model. As we move to our next chapter as a private company, I would like to thank our customers, partners, talented employees, and shareholders for their unwavering support."

ShowHide Related Items >><<
FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

FSCT ForeScout
$28.98 /

+0.01 (+0.03%)

Hot Stocks
ForeScout, Arista Networks announce strategic partnership » 06:14
08/05/20
08/05
06:14
08/05/20
06:14
FSCT

ForeScout

$28.97 /

+ (+0.00%)

, ANET

Arista Networks

$264.23 /

+3.72 (+1.43%)

Forescout Technologies…

Forescout Technologies (FSCT) announced a strategic partnership with Arista Networks (ANET) to reduce cybersecurity risks brought on by explosive growth of IoT devices, increased network complexity and propagation of malware. The partnership includes the development of a unique open ecosystem that embeds security within the network fabric and delivers full visibility and enforcement of critical enterprise assets. Through this new collaboration, Forescout integrates directly to and is certified on Arista's switches and wireless infrastructure, including the new line of Arista Cognitive Campus PoE switches. Forescout also supports Arista's network-wide workload orchestration and workflow automation solution CloudVision. Further, co-innovation is underway in the context of a Zero Trust architecture to identify IoT devices and ensure they are assigned to specific segments in order to reduce risk and prevent anomalous behavior.

ShowHide Related Items >><<
FSCT ForeScout
$28.97 /

+ (+0.00%)

ANET Arista Networks
$264.23 /

+3.72 (+1.43%)

FSCT ForeScout
$28.97 /

+ (+0.00%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
ANET Arista Networks
$264.23 /

+3.72 (+1.43%)

07/24/20 Wolfe Research
Arista Networks initiated with a Peer Perform at Wolfe Research
05/06/20 Wells Fargo
Arista Networks price target raised to $215 from $205 at Wells Fargo
05/06/20 Nomura Instinet
Arista Networks price target raised to $190 from $180 at Nomura Instinet
04/09/20 Piper Sandler
Arista Networks downgraded to Neutral from Overweight at Piper Sandler
FSCT ForeScout
$28.97 /

+ (+0.00%)

ANET Arista Networks
$264.23 /

+3.72 (+1.43%)

FSCT ForeScout
$28.97 /

+ (+0.00%)

FSCT ForeScout
$28.97 /

+ (+0.00%)

ANET Arista Networks
$264.23 /

+3.72 (+1.43%)

FSCT ForeScout
$28.97 /

+ (+0.00%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:36
07/15/20
07/15
16:36
07/15/20
16:36
BLL

Ball Corp.

$69.47 /

-4.16 (-5.65%)

, CCK

Crown Holdings

$67.10 /

-1.655 (-2.41%)

, GS

Goldman Sachs

$216.83 /

+2.54 (+1.19%)

, JPM

JPMorgan

$99.74 /

+1.52 (+1.55%)

, UNH

UnitedHealth

$304.14 /

-4.44 (-1.44%)

, MRNA

Moderna

$80.23 /

+5.19 (+6.92%)

, AZN

AstraZeneca

$57.98 /

+4.01 (+7.43%)

, WMT

Walmart

$131.99 /

-0.04 (-0.03%)

, FSCT

ForeScout

$28.89 /

+3.92 (+15.70%)

, ORGO

Organogenesis

$3.88 /

+0.63 (+19.38%)

, ARD

Ardagh Group

$13.47 /

+0.2 (+1.51%)

, BK

BNY Mellon

$36.85 /

-2.14 (-5.49%)

Stocks were rallying in…

Open Full Text

ShowHide Related Items >><<
WMT Walmart
$131.99 /

-0.04 (-0.03%)

UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

ORGO Organogenesis
$3.88 /

+0.63 (+19.38%)

MRNA Moderna
$80.23 /

+5.19 (+6.92%)

JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

CCK Crown Holdings
$67.10 /

-1.655 (-2.41%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

07/15/20 Jefferies
Canpack's new Scranton plant 'modest negative' for Ball, Crown, says Jefferies
07/15/20 Citi
Can-Pack entry to U.S. would be negative for Ball, Crown, says Citi
07/13/20 Jefferies
Ball Corp. assumed with a Hold at Jefferies
06/01/20 Atlantic Equities
Ball Corp. initiated with a Neutral at Atlantic Equities
CCK Crown Holdings
$67.10 /

-1.655 (-2.41%)

07/13/20 Jefferies
Crown Holdings assumed with a Buy at Jefferies
GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

07/16/20 DA Davidson
Goldman Sachs price target raised to $238 from $215 at DA Davidson
07/16/20 Oppenheimer
Goldman Sachs price target raised to $355 from $335 at Oppenheimer
07/16/20 RBC Capital
Goldman Sachs price target raised to $225 from $200 at RBC Capital
07/16/20 Credit Suisse
Goldman Sachs price target raised to $255 from $240 at Credit Suisse
JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

07/15/20 BMO Capital
JPMorgan price target raised to $119 from $108 at BMO Capital
07/09/20 Wolfe Research
JPMorgan upgraded to Outperform from Peer Perform at Wolfe Research
07/09/20 DA Davidson
JPMorgan upgraded to Buy from Neutral at DA Davidson
07/08/20 Seaport Global
JPMorgan initiated with a Buy at Seaport Global
UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

07/16/20 SVB Leerink
UnitedHealth price target raised to $370 from $360 at SVB Leerink
07/16/20 Oppenheimer
UnitedHealth price target raised to $353 from $343 at Oppenheimer
07/16/20 Deutsche Bank
UnitedHealth price target raised to $312 from $293 at Deutsche Bank
07/16/20 Credit Suisse
UnitedHealth price target raised to $335 from $325 at Credit Suisse
MRNA Moderna
$80.23 /

+5.19 (+6.92%)

07/16/20 B. Riley FBR
Novavax price target raised to $155 from $106 at B. Riley FBR
07/15/20 JPMorgan
JPMorgan 'encouraged' by results of Moderna COVID vaccine candidate
07/15/20 Piper Sandler
Moderna price target raised to $134 from $100 at Piper Sandler
07/15/20 Goldman Sachs
Moderna Phase 1 COVID-19 vaccine data 'impresses,' says Goldman Sachs
AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
WMT Walmart
$131.99 /

-0.04 (-0.03%)

07/14/20 Oppenheimer
Walmart+ could better defend against Amazon grocery threat, says Oppenheimer
07/12/20 Jefferies
Walmart/Target e-comm growth not seen coming at Amazon's expense, says Jefferies
07/10/20 Morgan Stanley
Walmart 'a sleeping giant to watch' in healthcare, says Morgan Stanley
07/09/20 Craig-Hallum
Craig-Hallum remains bullish on eHealth as Walmart helps validate opportunity
FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
ORGO Organogenesis
$3.88 /

+0.63 (+19.38%)

03/06/20 Credit Suisse
Organogenesis price target lowered to $8 from $10 at Credit Suisse
01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
ARD Ardagh Group
$13.47 /

+0.2 (+1.51%)

04/24/20 Barclays
Ardagh Group price target lowered to $15 from $22 at Barclays
04/17/20 Wells Fargo
Ardagh Group downgraded to Underweight from Equal Weight at Wells Fargo
01/16/20 Barclays
Ardagh Group initiated with an Equal Weight at Barclays
BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

07/08/20 Seaport Global
BNY Mellon initiated with a Buy at Seaport Global
07/08/20 Jefferies
BNY Mellon upgraded to Buy on positive EPS revisions at Jefferies
07/08/20 Jefferies
BNY Mellon upgraded to Buy from Hold at Jefferies
06/11/20 Deutsche Bank
BNY Mellon named short-term investment idea at Deutsche Bank
WMT Walmart
$131.99 /

-0.04 (-0.03%)

UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

ORGO Organogenesis
$3.88 /

+0.63 (+19.38%)

MRNA Moderna
$80.23 /

+5.19 (+6.92%)

JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

CCK Crown Holdings
$67.10 /

-1.655 (-2.41%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

ARD Ardagh Group
$13.47 /

+0.2 (+1.51%)

  • 19
    May
  • 12
    Feb
  • 22
    Nov
WMT Walmart
$131.99 /

-0.04 (-0.03%)

UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

MRNA Moderna
$80.23 /

+5.19 (+6.92%)

JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

WMT Walmart
$131.99 /

-0.04 (-0.03%)

UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

MRNA Moderna
$80.23 /

+5.19 (+6.92%)

JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

CCK Crown Holdings
$67.10 /

-1.655 (-2.41%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

WMT Walmart
$131.99 /

-0.04 (-0.03%)

UNH UnitedHealth
$304.14 /

-4.44 (-1.44%)

MRNA Moderna
$80.23 /

+5.19 (+6.92%)

JPM JPMorgan
$99.74 /

+1.52 (+1.55%)

GS Goldman Sachs
$216.83 /

+2.54 (+1.19%)

FSCT ForeScout
$28.89 /

+3.92 (+15.70%)

BLL Ball Corp.
$69.47 /

-4.16 (-5.65%)

BK BNY Mellon
$36.85 /

-2.14 (-5.49%)

AZN AstraZeneca
$57.98 /

+4.01 (+7.43%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:13
07/15/20
07/15
12:13
07/15/20
12:13
GS

Goldman Sachs

$217.30 /

+3.01 (+1.40%)

, UNH

UnitedHealth

$303.58 /

-5 (-1.62%)

, MRNA

Moderna

$78.67 /

+3.63 (+4.84%)

, WMT

Walmart

$132.49 /

+0.46 (+0.35%)

, FSCT

ForeScout

$28.88 /

+3.91 (+15.66%)

, ORGO

Organogenesis

$3.70 /

+0.45 (+13.85%)

, ZYXI

Zynex

$23.02 /

-3.18 (-12.14%)

, BK

BNY Mellon

$36.28 /

-2.71 (-6.95%)

Stocks were rallying in…

Open Full Text

ShowHide Related Items >><<
ZYXI Zynex
$23.02 /

-3.18 (-12.14%)

WMT Walmart
$132.49 /

+0.46 (+0.35%)

UNH UnitedHealth
$303.58 /

-5 (-1.62%)

ORGO Organogenesis
$3.70 /

+0.45 (+13.85%)

MRNA Moderna
$78.67 /

+3.63 (+4.84%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
UNH UnitedHealth
$303.58 /

-5 (-1.62%)

07/14/20 KeyBanc
UnitedHealth competition won't impact Livongo near term, says KeyBanc
07/07/20 Cantor Fitzgerald
UnitedHealth likely to reiterate 2020 outlook, says Cantor Fitzgerald
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
07/01/20 SVB Leerink
UnitedHealth reinstated with an Outperform at SVB Leerink
MRNA Moderna
$78.67 /

+3.63 (+4.84%)

07/15/20 JPMorgan
JPMorgan 'encouraged' by results of Moderna COVID vaccine candidate
07/15/20 Piper Sandler
Moderna price target raised to $134 from $100 at Piper Sandler
07/15/20 Goldman Sachs
Moderna Phase 1 COVID-19 vaccine data 'impresses,' says Goldman Sachs
07/14/20 Piper Sandler
Moderna COVID vaccine trial on track for July start, says Piper Sandler
WMT Walmart
$132.49 /

+0.46 (+0.35%)

07/14/20 Oppenheimer
Walmart+ could better defend against Amazon grocery threat, says Oppenheimer
07/12/20 Jefferies
Walmart/Target e-comm growth not seen coming at Amazon's expense, says Jefferies
07/10/20 Morgan Stanley
Walmart 'a sleeping giant to watch' in healthcare, says Morgan Stanley
07/09/20 Craig-Hallum
Craig-Hallum remains bullish on eHealth as Walmart helps validate opportunity
FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
ORGO Organogenesis
$3.70 /

+0.45 (+13.85%)

03/06/20 Credit Suisse
Organogenesis price target lowered to $8 from $10 at Credit Suisse
01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
ZYXI Zynex
$23.02 /

-3.18 (-12.14%)

07/13/20 B. Riley FBR
Zynex downgraded to Neutral on valuation at B. Riley FBR
07/13/20 B. Riley FBR
Zynex downgraded to Neutral from Buy at B. Riley FBR
07/10/20 H.C. Wainwright
Zynex price target raised to $30 from $20 at H.C. Wainwright
06/16/20 Northland
Zynex downgraded to Market Perform from Outperform at Northland
BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

07/08/20 Seaport Global
BNY Mellon initiated with a Buy at Seaport Global
07/08/20 Jefferies
BNY Mellon upgraded to Buy on positive EPS revisions at Jefferies
07/08/20 Jefferies
BNY Mellon upgraded to Buy from Hold at Jefferies
06/11/20 Deutsche Bank
BNY Mellon named short-term investment idea at Deutsche Bank
ZYXI Zynex
$23.02 /

-3.18 (-12.14%)

WMT Walmart
$132.49 /

+0.46 (+0.35%)

UNH UnitedHealth
$303.58 /

-5 (-1.62%)

ORGO Organogenesis
$3.70 /

+0.45 (+13.85%)

MRNA Moderna
$78.67 /

+3.63 (+4.84%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

  • 15
    Jul
  • 19
    May
  • 12
    Feb
  • 22
    Nov
WMT Walmart
$132.49 /

+0.46 (+0.35%)

UNH UnitedHealth
$303.58 /

-5 (-1.62%)

MRNA Moderna
$78.67 /

+3.63 (+4.84%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

WMT Walmart
$132.49 /

+0.46 (+0.35%)

UNH UnitedHealth
$303.58 /

-5 (-1.62%)

MRNA Moderna
$78.67 /

+3.63 (+4.84%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

WMT Walmart
$132.49 /

+0.46 (+0.35%)

UNH UnitedHealth
$303.58 /

-5 (-1.62%)

MRNA Moderna
$78.67 /

+3.63 (+4.84%)

GS Goldman Sachs
$217.30 /

+3.01 (+1.40%)

FSCT ForeScout
$28.88 /

+3.91 (+15.66%)

BK BNY Mellon
$36.28 /

-2.71 (-6.95%)

Hot Stocks
ForeScout, Advent International reach amended merger deal for $29 per share » 09:05
07/15/20
07/15
09:05
07/15/20
09:05
FSCT

ForeScout

$24.97 /

+0.05 (+0.20%)

Forescout Technologies…

Forescout Technologies announced that the companies have agreed to amend the terms of their previously announced transaction. The Forescout Board of Directors has unanimously approved a revised definitive agreement under which Advent will acquire all outstanding shares of Forescout common stock for $29.00 per share. Advent has partnered with Crosspoint Capital Partners, a private equity investment firm focused on cybersecurity and privacy industries, as an advisor on this transaction. Concurrently with executing the amended merger agreement, Forescout and Advent reached a settlement agreement as a result of which the pending litigation in the Delaware Court of Chancery will be dismissed. Forescout's Board and management will be further strengthened with the additions of Crosspoint Capital Partners' Greg Clark and Nicholas Noviello following commencement of the tender offer. Mr. Clark, Managing Partner of Crosspoint Capital Partners and former CEO of Symantec and Blue Coat, both leading cybersecurity companies, will join Forescout's Board of Directors. Mr. Noviello, former Executive Vice President and CFO of Symantec and of NetApp, and CFO of Blue Coat, has over 28 years of global finance and operations, process improvement and company transformation leadership experience, and will join Forescout as COO. Under the terms of the revised merger agreement, Advent will commence a tender offer on or before July 20, 2020, to acquire all of the outstanding shares of Forescout common stock for a price of $29.00 per share. The closing of the tender offer is subject to certain limited customary conditions, including the tender by Forescout shareholders of at least one share more than 50% of Forescout's issued and outstanding shares. Funds affiliated with Advent have committed to provide a full equity backstop in support of the transaction. The transaction is expected to close in the third quarter of 2020. Promptly following completion of the tender offer, Advent will acquire any shares of Forescout that are not tendered in the tender offer through a second-step merger under Delaware law for consideration equal to the tender offer price. Following the transaction, Forescout will become a privately held company with the flexibility to continue investing in the development and deployment of leading-edge cyber security products and solutions that serve the evolving needs of enterprise customers.

ShowHide Related Items >><<
FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

FSCT ForeScout
$24.97 /

+0.05 (+0.20%)

Over a month ago
Hot Stocks
ForeScout selected by DOE for INL project » 06:06
06/23/20
06/23
06:06
06/23/20
06:06
FSCT

ForeScout

$22.03 /

+0.33 (+1.52%)

Forescout Technologies…

Forescout Technologies announced it has been selected by the U.S. Department of Energy, or DOE, to participate in a project with Idaho National Laboratory, or INL, titled "Firmware Command and Control." The purpose of the Firmware Command and Control project is to identify potential vulnerabilities that exist in ubiquitous libraries by using machine learning similarity analysis of embedded code and sharing those findings in a structured format for processing across operational and information technology environments. In addition to INL, Forescout will also partner with Argonne National Laboratory, Sandia National Laboratories, and the National Renewable Energy Laboratory.

ShowHide Related Items >><<
FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

FSCT ForeScout
$22.03 /

+0.33 (+1.52%)

Periodicals
ForeScout tells Bloomberg allegations related to ordinary course transaction » 14:40
06/05/20
06/05
14:40
06/05/20
14:40
FSCT

ForeScout

$22.98 /

-1.25 (-5.16%)

ForeScout, in emailed…

ForeScout, in emailed comments to Bloomberg, said that allegations made against the company were related to an ordinary course transaction with one of the company's largest customers and the the company has been paid in full, as confirmed by the company's auditor. Earlier in the session ForeScout shares had fallen sharply after a court filing revealed that Advent sought a subpoena related to a whistle-blower email that alleged ForeScout involved Merlin in an alleged "channel stuffing scheme" in 2019. In May, Forescout announced that it has filed a complaint with the Delaware Court of Chancery asserting that affiliates of Advent International Corporation violated the terms of their merger agreement with Forescout.

ShowHide Related Items >><<
FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

05/29/20 UBS
ForeScout price target lowered to $25 from $36 at UBS
02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

FSCT ForeScout
$22.98 /

-1.25 (-5.16%)

Recommendations
ForeScout price target lowered to $25 from $36 at UBS » 06:37
05/29/20
05/29
06:37
05/29/20
06:37
FSCT

ForeScout

$24.51 /

-0.23 (-0.93%)

UBS analyst Fatima…

UBS analyst Fatima Boolani lowered the firm's price target on ForeScout to $25 from $36 and keeps a Neutral rating on the shares. The analyst believes that the company's legal action with Advent following its May 18th notice of withdrawn intention to consummate the planned take-private deal will result in execution distractions, potentially impacting the rate and pace of sales execution recovery for new business.

ShowHide Related Items >><<
FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

FSCT ForeScout
$24.51 /

-0.23 (-0.93%)

Options
ForeScout Technologies call volume above normal and directionally bullish » 15:25
05/22/20
05/22
15:25
05/22/20
15:25
FSCT

ForeScout

$23.19 /

+2.84 (+13.96%)

Bullish option flow…

Bullish option flow detected in ForeScout Technologies with 25,742 calls trading, 8x expected, and implied vol increasing over 5 points to 84.23%. Jun-20 25 calls and Jun-20 22.5 calls are the most active options, with total volume in those strikes near 15,000 contracts. The Put/Call Ratio is 0.17. Earnings are expected on August 5th.

ShowHide Related Items >><<
FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

Hot Stocks
ForeScout commences litigation against Advent International » 08:22
05/20/20
05/20
08:22
05/20/20
08:22
FSCT

ForeScout

$20.93 /

-1.62 (-7.18%)

Forescout filed a…

Forescout filed a complaint with the Delaware Court of Chancery asserting that affiliates of Advent International Corporation have violated the terms of their merger agreement with Forescout. Forescout is asking the Court to compel Advent to honor its commitments and immediately complete the pending acquisition of Forescout. On May 15, 2020, Advent notified Forescout that it would not consummate the acquisition on May 18, 2020, as scheduled. Advent's purported excuse for its wrongful conduct is that a closing condition to the transaction has not been satisfied because a "material adverse effect" has occurred at Forescout. Forescout believes that no material adverse effect has occurred, that all closing conditions are satisfied, and that Advent is obligated to close the transaction. Forescout believes that Advent has relied on meritless excuses to support its position. The merger agreement explicitly allocated the risk of any impacts from COVID-19 to Advent. Since announcing the transaction, Forescout shareholders overwhelmingly approved the transaction. Prior to announcing the Advent transaction on February 6, 2020, the Forescout Board conducted a robust and comprehensive process with the assistance of independent legal and financial advisors. Advent is a sophisticated and experienced investor, and over the course of its due diligence investigation - which lasted hundreds of hours over multiple months - Forescout shared with Advent all relevant information, including detailed financial and technical information as well as Forescout's internal estimates and projections. The Forescout Board and management team dedicated significant time and resources to providing Advent with detailed and transparent information in response to its every request, ensuring that Advent had a complete picture of Forescout's business and market opportunity.

ShowHide Related Items >><<
FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

FSCT ForeScout
$20.93 /

-1.62 (-7.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.